"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Concept/Terms
Adjuvants, Immunologic- Adjuvants, Immunologic
- Adjuvants, Immunological
- Immunological Adjuvants
- Immunological Adjuvant
- Adjuvant, Immunological
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunopotentiators
- Immunoactivators
- Immunoadjuvants
- Immunostimulants
- Immunologic Adjuvants
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in Harvard Catalyst Profiles by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 2 | 3 |
| 1992 | 2 | 1 | 3 |
| 1993 | 1 | 6 | 7 |
| 1994 | 5 | 2 | 7 |
| 1995 | 3 | 6 | 9 |
| 1996 | 7 | 2 | 9 |
| 1997 | 12 | 7 | 19 |
| 1998 | 7 | 4 | 11 |
| 1999 | 8 | 9 | 17 |
| 2000 | 12 | 8 | 20 |
| 2001 | 9 | 14 | 23 |
| 2002 | 21 | 10 | 31 |
| 2003 | 22 | 18 | 40 |
| 2004 | 18 | 6 | 24 |
| 2005 | 14 | 12 | 26 |
| 2006 | 17 | 9 | 26 |
| 2007 | 12 | 6 | 18 |
| 2008 | 11 | 13 | 24 |
| 2009 | 4 | 14 | 18 |
| 2010 | 7 | 8 | 15 |
| 2011 | 9 | 8 | 17 |
| 2012 | 10 | 15 | 25 |
| 2013 | 12 | 12 | 24 |
| 2014 | 9 | 13 | 22 |
| 2015 | 16 | 8 | 24 |
| 2016 | 12 | 15 | 27 |
| 2017 | 11 | 9 | 20 |
| 2018 | 7 | 6 | 13 |
| 2019 | 5 | 16 | 21 |
| 2020 | 13 | 8 | 21 |
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. Ann Surg Oncol. 2020 Dec; 27(13):5137-5138.
-
Bacillus subtilis spores as adjuvants against avian influenza H9N2 induce antigen-specific antibody and T cell responses in White Leghorn chickens. Vet Res. 2020 May 24; 51(1):68.
-
IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants. J Allergy Clin Immunol. 2020 09; 146(3):652-666.e11.
-
DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 08 14; 369(6505):806-811.
-
Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020 07; 88(1):42-55.
-
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. J Virol. 2020 04 16; 94(9).
-
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020 05 05; 94(18):e1950-e1960.
-
A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis. J Am Acad Dermatol. 2020 Dec; 83(6):1807-1809.
-
A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. Pediatr Infect Dis J. 2020 04; 39(4):345-351.
-
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urol Oncol. 2020 05; 38(5):459-464.